Recent Chronic Lymphoblastic Leukemia News

Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia (May 20, 2019)

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic... Continue Reading